Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 4/2016

01-12-2016 | Screening and Imaging (HTC Le-Petross, Section Editor)

Breast MRI Screening: Benefits and Limitations

Authors: Samantha L. Heller, Linda Moy

Published in: Current Breast Cancer Reports | Issue 4/2016

Login to get access

Abstract

Multiple studies have demonstrated screening mammography’s ability to decrease mortality in average risk women. It is also recognized that women at high risk for breast cancer who choose surveillance benefit from additional imaging strategies for cancer detection in addition to mammography alone. Contrast-enhanced breast MRI has become a standard and accepted tool in the screening evaluation of women with a high risk of breast cancer. However, despite recognition of MRI’s ability to detect breast cancer in the screening setting in a high-risk population, there are still questions surrounding the use of breast MRI in the screening environment. This chapter will provide an overview of breast screening MRI indications and current guidelines and will also review the evidence supporting the use of screening breast MRI.
Literature
1.
2.
3.
Heywang-Kobrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care (Basel). 2011;6(3):199–207.CrossRef
4.
5.
Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.CrossRefPubMed
6.
Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. National Institute for Health and Clinical Excellence: Guidance. Cardiff (UK)2013.
7.
8.
Mann RM, Balleyguier C, Baltzer PA, Bick U, Colin C, Cornford E, et al. Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol. 2015;25(12):3669–78.CrossRefPubMedPubMedCentral
9.
Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 hereditary breast and ovarian cancer. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA)1993.
10.
Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res. 2007;13(24):7357–62.CrossRefPubMed
11.
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90(15):1138–45.CrossRefPubMed
12.
Gilbert FJ, Warren RM, Kwan-Lim G, Thompson DJ, Eeles RA, Evans DG, et al. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology. 2009;252(2):358–68.CrossRefPubMed
13.
Klijn JG. Early diagnosis of hereditary breast cancer by magnetic resonance imaging: what is realistic? J Clin Oncol. 2010;28(9):1441–5.CrossRefPubMed
14.
Warwick J, Birke H, Stone J, Warren RM, Pinney E, Brentnall AR, et al. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res. 2014;16(5):451.CrossRefPubMedPubMedCentral
15.
Sestak I, Cuzick J. Update on breast cancer risk prediction and prevention. Curr Opin Obstet Gynecol. 2015;27(1):92–7.CrossRefPubMed
16.
Hollingsworth AB, Stough RG. An alternative approach to selecting patients for high-risk screening with breast MRI. Breast J. 2014;20(2):192–7.CrossRefPubMed
17.
Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469–76.CrossRefPubMed
18.
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427–37.CrossRefPubMed
19.
Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769–78.CrossRefPubMed
20.
• Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer. 2016;114(6):631–7. This source adds to the literature refining which imaging studies may be most effective for specific high risk groups.CrossRefPubMed
21.
Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, et al. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1458–68.CrossRefPubMed
22.
Mulder RL, Kremer LC, Hudson MM, Bhatia S, Landier W, Levitt G, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2013;14(13):e621–9.CrossRefPubMedPubMedCentral
23.
Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013;31(18):2282–8.CrossRefPubMed
24.
Tieu MT, Cigsar C, Ahmed S, Ng A, Diller L, Millar BA, et al. Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. Cancer. 2014;120(16):2507–13.CrossRefPubMed
25.
Freitas V, Scaranelo A, Menezes R, Kulkarni S, Hodgson D, Crystal P. Added cancer yield of breast magnetic resonance imaging screening in women with a prior history of chest radiation therapy. Cancer. 2013;119(3):495–503.CrossRefPubMed
26.
Zeng L, Lo G, Moshonov H, Liang J, Hodgson D, Crystal P. Breast background parenchymal enhancement on screening magnetic resonance imaging in women who received chest radiotherapy for childhood Hodgkin’s lymphoma. Acad Radiol. 2016;23(2):168–75.CrossRefPubMed
27.
Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18–27.CrossRefPubMed
28.
Brennan S, Liberman L, Dershaw DD, Morris E. Breast MRI screening of women with a personal history of breast cancer. AJR Am J Roentgenol. 2010;195(2):510–6.CrossRefPubMed
29.
• Gweon HM, Cho N, Han W, Yi A, Moon HG, Noh DY, et al. Breast MR imaging screening in women with a history of breast conservation therapy. Radiology. 2014;272(2):366–73. This article adds to the recent literature evaluating the use of screening breast MRI in women with a personal history of breast cancer.CrossRefPubMed
30.
Schacht DV, Yamaguchi K, Lai J, Kulkarni K, Sennett CA, Abe H. Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: results from screening breast MRI. AJR Am J Roentgenol. 2014;202(2):289–92.CrossRefPubMed
31.
• Giess CS, Poole PS, Chikarmane SA, Sippo DA, Birdwell RL. Screening breast MRI in patients previously treated for breast cancer: diagnostic yield for cancer and abnormal interpretation rate. Acad Radiol. 2015;22(11):1331–7. This article adds to the recent literature evaluating the use of screening breast MRI in women with a personal history of breast cancer.CrossRefPubMed
32.
• Lehman CD, Lee JM, DeMartini WB, Hippe DS, Rendi MH, Kalish G, et al. Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst. 2016;108(3). This article adds to the recent literature evaluating the use of screening breast MRI in women with a personal history of breast cancer.
33.
• Destounis S, Arieno A, Morgan R. Personal history of premenopausal breast cancer as a risk factor for referral to screening breast MRI. Acad Radiol. 2016;23(3):353–7. This article adds to the recent literature evaluating the use of screening breast MRI in women with a personal history of breast cancer.CrossRefPubMed
34.
Friedlander LC, Roth SO, Gavenonis SC. Results of MR imaging screening for breast cancer in high-risk patients with lobular carcinoma in situ. Radiology. 2011;261(2):421–7.CrossRefPubMed
35.
Sung JS, Malak SF, Bajaj P, Alis R, Dershaw DD, Morris EA. Screening breast MR imaging in women with a history of lobular carcinoma in situ. Radiology. 2011;261(2):414–20.CrossRefPubMed
36.
King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, et al. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat. 2013;142(2):445–53.CrossRefPubMed
37.
Schwartz T, Cyr A, Margenthaler J. Screening breast magnetic resonance imaging in women with atypia or lobular carcinoma in situ. J Surg Res. 2015;193(2):519–22.CrossRefPubMed
38.
Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 2011;13(6):223.CrossRefPubMedPubMedCentral
39.
McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–69.CrossRefPubMed
40.
Othman E, Wang J, Sprague BL, Rounds T, Ji Y, Herschorn SD, et al. Comparison of false positive rates for screening breast magnetic resonance imaging (MRI) in high risk women performed on stacked versus alternating schedules. Springerplus. 2015;4:77.CrossRefPubMedPubMedCentral
41.
Mason C, Yokubaitis K, Howard E, Shah Z, Wang J. Impact of Henda’s law on the utilization of screening breast magnetic resonance imaging. Proc (Bayl Univ Med Cent). 2015;28(1):7–9.
42.
Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausto A, Simonetti G, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol. 2004;183(4):1149–57.CrossRefPubMed
43.
Wright H, Listinsky J, Rim A, Chellman-Jeffers M, Patrick R, Rybicki L, et al. Magnetic resonance imaging as a diagnostic tool for breast cancer in premenopausal women. Am J Surg. 2005;190(4):572–5.CrossRefPubMed
44.
Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394–404.CrossRefPubMedPubMedCentral
45.
•• Emaus MJ, Bakker MF, Peeters PH, Loo CE, Mann RM, de Jong MD, et al. MR imaging as an additional screening modality for the detection of breast cancer in women aged 50–75 years with extremely dense breasts: the DENSE Trial Study Design. Radiology. 2015;277(2):527–37. This reference details a study to determine the additional value of MRI for breast cancer screening in women with dense breasts.CrossRefPubMed
46.
Schrading S, Kuhl C. MRI screening of women at average risk of breast cancer. J Clin Oncol 31, 2013 (suppl 26; abstr 21).
47.
Harvey SC, Di Carlo PA, Lee B, Obadina E, Sippo D, Mullen L. An abbreviated protocol for high-risk screening breast MRI saves time and resources. J Am Coll Radiol. 2016;13(4):374–80.CrossRefPubMed
48.
• Grimm LJ, Soo MS, Yoon S, Kim C, Ghate SV, Johnson KS. Abbreviated screening protocol for breast MRI: a feasibility study. Acad Radiol. 2015;22(9):1157–62. This reference details a study to determine the additional value of MRI for breast cancer screening in women with dense breasts.CrossRefPubMed
49.
Heacock L, Melsaether AN, Heller SL, Gao Y, Pysarenko KM, Babb JS, et al. Evaluation of a known breast cancer using an abbreviated breast MRI protocol: correlation of imaging characteristics and pathology with lesion detection and conspicuity. Eur J Radiol. 2016;85(4):815–23.CrossRefPubMed
50.
• Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection—a novel approach to breast cancer screening with MRI. J Clin Oncol. 2014;32(22):2304–10. This reference details a study to determine the additional value of MRI for breast cancer screening in women with dense breasts.CrossRefPubMed
51.
• Mango VL, Morris EA, David Dershaw D, Abramson A, Fry C, Moskowitz CS, et al. Abbreviated protocol for breast MRI: are multiple sequences needed for cancer detection? Eur J Radiol. 2015;84(1):65–70. This reference details a study to determine the additional value of MRI for breast cancer screening in women with dense breasts.CrossRefPubMed
52.
Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, Konig R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28(9):1450–7.CrossRefPubMed
53.
Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664–9.CrossRefPubMedPubMedCentral
54.
Evans DG, Kesavan N, Lim Y, Gadde S, Hurley E, Massat NJ, et al. MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat. 2014;145(3):663–72.CrossRefPubMed
55.
Evans DG, Harkness EF, Howell A, Wilson M, Hurley E, Holmen MM, et al. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hered Cancer Clin Pract. 2016;14:8.CrossRefPubMedPubMedCentral
56.
Santoro F, Podo F, Sardanelli F. MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis. Breast Cancer Res Treat. 2014;147(3):685–7.CrossRefPubMed
57.
Hodgson DC, Cotton C, Crystal P, Nathan PC. Impact of early breast cancer screening on mortality among young survivors of childhood Hodgkin’s lymphoma. J Natl Cancer Inst. 2016;108(7).
58.
Warner E. The role of magnetic resonance imaging in screening women at high risk of breast cancer. Top Magn Reson Imaging. 2008;19(3):163–9.CrossRefPubMed
59.
Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011;117(17):3900–7.CrossRefPubMed
60.
Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer. 2012;118(8):2021–30.CrossRefPubMed
61.
•• Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, et al. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age >/= 50 years: evidence from an individual patient data meta-analysis. J Clin Oncol. 2015;33(4):349–56. This study demonstrates the higher sensitivity of MR and mammographic screening for detecting cancer compared to mammographic screening alone in women older than 50 years of age.CrossRefPubMed
62.
Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer. 2006;95(7):801–10.CrossRefPubMedPubMedCentral
63.
Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295(20):2374–84.CrossRefPubMed
64.
Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, et al. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst. 2013;105(17):1314–21.CrossRefPubMed
65.
•• Niell BL, Gavenonis SC, Motazedi T, Chubiz JC, Halpern EP, Rafferty EA, et al. Auditing a breast MRI practice: performance measures for screening and diagnostic breast MRI. J Am Coll Radiol. 2014;11(9):883–9. This reference provides an analysis of key outcome measures for auditing a breast MRI screening program.CrossRefPubMedPubMedCentral
66.
Sickles EDOC. ACR BI-RADS® Follow-up and outcome monitoring. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
67.
Haas JS, Hill DA, Wellman RD, Hubbard RA, Lee CI, Wernli KJ, et al. Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. Cancer. 2016;122(4):611–7.CrossRefPubMed
68.
Onega T, Hubbard R, Hill D, Lee CI, Haas JS, Carlos HA, et al. Geographic access to breast imaging for US women. J Am Coll Radiol. 2014;11(9):874–82.CrossRefPubMedPubMedCentral
69.
Onega T, Lee CI, Benkeser D, Alford-Teaster J, Haas JS, Tosteson AN, et al. Travel burden to breast MRI and utilization: are risk and sociodemographics related? J Am Coll Radiol. 2016;13(6):611–9.CrossRefPubMed
Metadata
Title
Breast MRI Screening: Benefits and Limitations
Authors
Samantha L. Heller
Linda Moy
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 4/2016
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-016-0230-7

Other articles of this Issue 4/2016

Current Breast Cancer Reports 4/2016 Go to the issue

Screening and Imaging (HTC Le-Petross, Section Editor)

Advanced Breast MRI Techniques: Helpful for Screening Breast Cancer?

Systemic Therapies (M Liu and T Haddad, Section Editors)

Management of Potential Long-Term Toxicities in Breast Cancer Patients

Systemic Therapies (M Liu and T Haddad, Section Editors)

Novel Strategies in Hormone Receptor-Positive Advanced Breast Cancer: Overcoming Endocrine Resistance

Screening and Imaging (HTC Le-Petross, Section Editor)

Molecular Breast Imaging: Role as a Screening Modality

Screening and Imaging (HTC Le-Petross, Section Editor)

Screening Breast Cancer: the Mammography War

Screening and Imaging (HTC Le-Petross, Section Editor)

Dedicated Breast CT: Screening Technique of the Future
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits